14.3 Anti-Obesity Pharmacotherapy (GLP-1/GIP) & Bariatric Surgery Considerations

14.3 Anti-Obesity Pharmacotherapy (GLP-1/GIP) & Bariatric Surgery Considerations

[!NOTE] Clinical Competency Core: The management of obesity has undergone a transformative paradigm shift from purely behavioral advice to biological and metabolic disease intervention. Incretin-based pharmacotherapies (GLP-1 receptor agonists and dual GIP/GLP-1 agonists) and metabolic/bariatric surgery (MBS) achieve unprecedented weight loss and robust reductions in major adverse cardiovascular events (MACE). Cardiac rehabilitation professionals must master the clinical trial evidence, hemodynamic impacts, drug-exercise interactions, and post-surgical precautions (e.g., dumping syndrome, rapid dehydration, lean muscle wasting) associated with these advanced therapies.

Obesity is a relapsing, neurochemical, and hormonal disorder driven by central dysregulation of energy homeostasis. While comprehensive lifestyle modification remains the foundational bedrock of cardiac rehabilitation, biological counter-regulations frequently limit long-term behavioral weight reduction to 5% to 7%. For patients with substantial residual cardiovascular risk, clinical guidelines mandate considering advanced pharmacotherapeutic and surgical metabolic therapies.

---

Clinical Indications for Anti-Obesity Pharmacotherapy

The U.S. Food and Drug Administration (FDA) and clinical practice guidelines from the Endocrine Society, AHA/ACC, and AACVPR establish standard criteria for initiating prescription anti-obesity pharmacotherapy as an adjunct to a reduced-calorie diet and increased physical activity:

• BMI ≥ 30.0 kg/m² (generalized obesity), OR
• BMI ≥ 27.0 kg/m² (overweight) in the presence of at least one weight-related comorbid condition:
  • Hypertension
  • Dyslipidemia (hypertriglyceridemia, low HDL-C, atherogenic dyslipidemia)
  • Type 2 Diabetes Mellitus or Prediabetes
  • Established Atherosclerotic Cardiovascular Disease (CAD, prior MI, prior PCI/CABG)
  • Obstructive Sleep Apnea (OSA)

Pharmacotherapy represents a chronic disease treatment model; discontinuing medications typically triggers biological rebound, with regain of up to two-thirds of lost weight within one year.

---

Incretin-Based Anti-Obesity Medications: GLP-1 and Dual GIP/GLP-1 Agonists

Incretin hormones—glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP)—are peptide hormones secreted by enteroendocrine L-cells and K-cells of the gastrointestinal tract in response to nutrient ingestion. Synthetic incretin receptor agonists leverage these evolutionary pathways to modulate appetite, glucose regulation, and cardiovascular physiology.

flowchart TD
    subgraph Incretin["Incretin System Activation"]
        GLP1["GLP-1 Receptor Agonism<br/>(Semaglutide / Tirzepatide)"]
        GIP["GIP Receptor Agonism<br/>(Tirzepatide)"]
    end

    subgraph Central["Central Hypothalamic & Brainstem Actions"]
        ARC["Arcuate Nucleus Activation<br/>(Stimulates POMC/CART, Inhibits NPY/AgRP)"]
        SATIETY["Profound Satiety & Suppressed Food Cravings"]
    end

    subgraph Peripheral["Gastrointestinal & Systemic Effects"]
        STOMACH["Delayed Gastric Emptying<br/>(Prolonged Postprandial Fullness)"]
        PANCREAS["Glucose-Dependent Insulin Release<br/>& Glucagon Suppression"]
        ADIPOSE["Improved Adipocyte Lipid Buffering<br/>& Reduced Ectopic Fat"]
    end

    subgraph ClinicalOutcomes["Cardiovascular & Weight Outcomes"]
        LOSS["Profound Weight Reduction<br/>(Semaglutide ~15%, Tirzepatide ~21–25%)"]
        SELECT["SELECT Trial: 20% MACE Reduction<br/>(Cardiovascular Death, MI, Stroke)"]
        HEMO["BP Reduction (3–5 mmHg)<br/>Slight HR Increase (+2–4 bpm)"]
    end

    GLP1 & GIP --> ARC --> SATIETY
    GLP1 --> STOMACH & PANCREAS
    GIP --> ADIPOSE
    SATIETY & STOMACH --> LOSS
    LOSS & GLP1 --> SELECT & HEMO

    style Incretin fill:#e1f5fe,stroke:#0288d1,color:#000
    style Central fill:#ede7f6,stroke:#512da8,color:#000
    style Peripheral fill:#fff3e0,stroke:#f57c00,color:#000
    style ClinicalOutcomes fill:#e8f5e9,stroke:#2e7d32,color:#000

1. Semaglutide 2.4 mg Weekly (Wegovy)

Semaglutide is a long-acting human GLP-1 receptor agonist with 94% structural homology to native GLP-1, engineered with an albumin-binding fatty acid diacid chain that extends its half-life to approximately 1 week.

• Weight Loss Efficacy (STEP Program): In the landmark STEP-1 trial (Semaglutide Treatment Effect in People with Obesity), subcutaneous semaglutide 2.4 mg once weekly combined with lifestyle intervention produced an average 14.9% mean reduction in body weight at 68 weeks (compared to 2.4% with placebo).
• The SELECT Cardiovascular Outcomes Trial (NEJM 2023): The SELECT trial was a paradigm-defining multi-center, double-blind, randomized controlled trial that enrolled 17,604 patients aged ≥45 years with established cardiovascular disease (prior MI, prior ischemic stroke, or symptomatic peripheral arterial disease) and a BMI ≥27 kg/m² who had NO history of diabetes mellitus. Over a mean follow-up of 39.8 months (3.3 years):
  • Primary Outcome: Once-weekly subcutaneous semaglutide 2.4 mg achieved a statistically significant 20% relative risk reduction in 3-point MACE (composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke; hazard ratio 0.80, 95% CI 0.72–0.90, p < 0.001).
  • Secondary Endpoints: Significant reductions in cardiovascular death (HR 0.85), heart failure composite events (HR 0.82), and all-cause mortality (HR 0.81).
  • Clinical Significance: SELECT proved unequivocally that targeted weight reduction via incretin therapy confers direct ischemic cardiovascular protection in secondary prevention patients without diabetes, moving anti-obesity pharmacotherapy directly into standard secondary prevention alongside statins, antiplatelet therapy, and beta-blockers.

2. Tirzepatide (Zepbound)

Tirzepatide is a novel synthetic unimolecular dual GIP and GLP-1 receptor agonist administered subcutaneously once weekly.

• Weight Loss Efficacy (SURMOUNT Program): In the SURMOUNT-1 trial, tirzepatide at doses of 5 mg, 10 mg, and 15 mg once weekly produced dose-dependent mean weight reductions of 15.0%, 19.5%, and 20.9% (up to 25.3% in on-treatment analysis) at 72 weeks in adults with obesity without diabetes.
• Metabolic & Cardiovascular Effects: Tirzepatide produces profound reductions in visceral and intra-hepatic fat, lowers systolic blood pressure by an average of 6 to 8 mmHg, improves lipid subfractions, and significantly improves apnea-hypopnea index (AHI) scores in obstructive sleep apnea.

3. Liraglutide 3.0 mg Daily (Saxenda)

A daily subcutaneous GLP-1 receptor agonist evaluated in the SCALE trial program, producing an average 8.0% weight loss. In the LEADER trial (at 1.8 mg daily in diabetic patients), liraglutide demonstrated a 13% reduction in 3-point MACE. Due to once-daily dosing and lower efficacy compared to weekly semaglutide and tirzepatide, it is primarily utilized as a second-line incretin option.

---

Comparison of Anti-Obesity Pharmacotherapies & Cardiac Rehabilitation Considerations

Clinical Warning: Preserving Lean Muscle Mass During Incretin Therapy

In both the STEP and SURMOUNT clinical trials, body composition substudies demonstrated that 25% to 40% of total weight lost during rapid incretin-mediated weight reduction derived from lean skeletal muscle mass (fat-free mass). In older cardiac rehabilitation patients, losing lean mass exacerbates sarcopenia, impairs balance, reduces bone mineral density, and compromises long-term functional autonomy.

Cardiac Rehabilitation Intervention: Clinicians must ensure that any patient on incretin therapy performs progressive resistance training at least 2 to 3 days per week (1–3 sets of 10–15 repetitions, RPE 11–14 on Borg 6–20 scale) and consumes targeted dietary protein (1.2 to 1.6 g/kg of ideal body weight per day) to stimulate muscle protein synthesis.

---

Metabolic and Bariatric Surgery (MBS)

Metabolic and bariatric surgery represents the most potent and durable intervention for severe obesity and associated cardiometabolic disease.

Updated Indications (2022 ASMBS / IFSO Guidelines)

In 2022, the American Society for Metabolic and Bariatric Surgery (ASMBS) and the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) updated the historical 1991 NIH criteria:

• BMI ≥ 35.0 kg/m² regardless of the presence, absence, or severity of comorbid conditions.
• BMI 30.0 to 34.9 kg/m² in patients with metabolic disease, including type 2 diabetes mellitus refractory to lifestyle and medical therapy, severe hypertension, obstructive sleep apnea, or non-alcoholic steatohepatitis (NASH).
• Asian Populations: Thresholds are adjusted downward: BMI ≥ 27.5 kg/m² qualifies for metabolic surgery.

Primary Surgical Procedures

1. Sleeve Gastrectomy (SG): The surgeon transects and removes approximately 75% to 80% of the greater curvature of the stomach, creating a narrow, tubular gastric sleeve along the lesser curvature. It operates primarily as a restrictive procedure and markedly suppresses circulating ghrelin by resecting the gastric fundus.
2. Roux-en-Y Gastric Bypass (RYGB): The surgeon creates a small (<30 mL) proximal gastric pouch, which is directly anastomosed to the mid-jejunum via a Roux limb (gastrojejunostomy). The excluded gastric remnant, duodenum, and proximal jejunum form the biliopancreatic limb, which is reconnected distally. RYGB provides both restrictive and mild malabsorptive mechanisms, triggering profound, rapid postprandial secretion of endogenous GLP-1, PYY, and oxyntomodulin.

Long-Term Cardiovascular Outcomes

Landmark prospective long-term trials—including the Swedish Obese Subjects (SOS) study and the STAMPEDE trial—demonstrate that bariatric surgery achieves:

• Long-term sustained weight loss of 25% to 35% at 10 to 20 years.
• Complete or partial remission of type 2 diabetes in 50% to 75% of patients.
• A 30% to 50% relative reduction in long-term cardiovascular mortality, with dramatic decreases in fatal and nonfatal myocardial infarction, stroke, and new-onset heart failure.

---

Post-Bariatric Surgery Management in Cardiac Rehabilitation

When a post-bariatric surgery patient enters Phase II cardiac rehabilitation, the clinical team must implement specialized monitoring protocols:

1. Differentiating Early vs. Late Dumping Syndrome

Dumping syndrome is an acute, distressing physiological complication following gastric surgery (particularly RYGB):

2. Hydration Balance and Orthostasis

Because the anatomical gastric pouch or sleeve holds only 30 to 100 mL, post-bariatric patients cannot consume large fluid boluses. Inability to drink adequate water during or after aerobic exercise rapidly leads to dehydration, decreased intravascular volume, and exertional orthostatic hypotension. Clinicians must instruct patients to continuously sip water throughout the day (targeting 1.5 to 2.0 liters/day) while avoiding fluids 30 minutes before and after meals.

3. Micronutrient Surveillance

Malabsorptive procedures (RYGB) impair absorption of iron, vitamin B12, folate, calcium, and fat-soluble vitamins (A, D, E, K). In cardiac rehabilitation:

• Iron and B12 Deficiencies: Provoke microcytic or macrocytic anemia, manifesting as unexplained exertional fatigue, disproportionate dyspnea, and tachycardia during exercise training.
• Calcium & Vitamin D Deficiencies: Accelerate bone mineral loss, requiring avoidance of high-impact ballistic exercises.

4. Incisional Healing & Exercise Resumption

• Aerobic Exercise: Low-impact walking can resume immediately post-hospital discharge.
• Resistance Training: Upper-body and core resistance exercises must be deferred for 4 to 6 weeks post-laparoscopy (longer if open laparotomy) until cleared by the bariatric surgical team, preventing incisional hernia formation and protecting the healing abdominal fascia. Clinicians avoid Valsalva maneuvers and high intra-abdominal pressures.

---

Clinical Case Scenario: GLP-1 Therapy and Sarcopenia Prevention in Post-CABG Rehabilitation

Patient Presentation: A 58-year-old male with severe three-vessel CAD, hypertension, and Class II obesity (BMI 36.4 kg/m², baseline weight 115 kg / 253 lbs) enrolls in Phase II cardiac rehabilitation 6 weeks following CABG x3. His cardiologist started him on subcutaneous semaglutide 2.4 mg weekly 1 month ago. The patient reports having lost 5 kg (11 lbs) in 4 weeks, but states: "I feel terribly weak. My legs shake when I climb stairs, and I have zero appetite."

Clinical Evaluation & Findings:

• Nutritional Intake: Patient is consuming barely 900 kcal/day with <35 g/day of protein due to persistent medication-induced nausea and early satiety.
• Physical Assessment: Sternal incision is well-healed and stable without clicks or separation. Grip strength has decreased by 18% compared to pre-operative baseline. Resting heart rate is 84 bpm (elevated by 6 bpm from pre-CABG baseline on metoprolol succinate 50 mg daily).

Clinical Decision-Making & CR Care Plan:

1. Identify Incretin-Induced Sarcopenia Risk: The CR team recognizes that his rapid weight loss consists disproportionately of skeletal muscle catabolism driven by extreme caloric restriction (<1,000 kcal/day) and inadequate protein intake.
2. Nutritional Prescription: In collaboration with the CR registered dietitian, his daily protein target is established at 1.3 g/kg of ideal body weight (~95–105 g/day), utilizing easily digestible whey protein isolate shakes and divided small protein snacks taken throughout the day.
3. Medication Adjustment: The team coordinates with the prescribing cardiologist to temporarily step down the semaglutide dose to 1.0 mg weekly until gastrointestinal side effects resolve and adequate nutritional intake is re-established.
4. Structured Resistance Training: Having passed 6 weeks post-CABG with a stable sternum, the clinician initiates light resistance training (elastic bands and light dumbbells: seated chest press, seated row, leg press; 1 set of 12 repetitions at RPE 11) to stimulate myofibrillar protein synthesis and reverse skeletal muscle loss.